Epigenetic modifiers to enhance the efficacy of immune checkpoint inhibitors for the treatment of melanoma

Abstract excerpt

Immune checkpoint inhibitor (ICI)-based immunotherapy has significantly improved survival outcomes and radically changed the management of many different types of solid tumors, including melanoma. Almost half of advanced melanoma patients achieve a long-term clinical benefit from ICIs. Unfortunately, the other half of treated patients either rapidly progress or achieve a short-term clinical benefit due to the...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Immunotherapy and Biomarkers
• Share to Epigenetics and DNA Methylation
• Share to Histone Deacetylase Inhibitors Research